Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Director Thomas John Dietz purchased 4,000 shares of the stock in a transaction on Friday, January 10th. The stock was acquired at an average price of $13.84 per share, with a total value of $55,360.00. Following the acquisition, the director now directly owns 24,000 shares in the company, valued at $332,160. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of NASDAQ:EIGR traded down $0.28 on Friday, hitting $11.83. The company’s stock had a trading volume of 132,788 shares, compared to its average volume of 292,959. Eiger Biopharmaceuticals Inc has a 12 month low of $9.38 and a 12 month high of $15.82. The company has a market capitalization of $298.60 million, a price-to-earnings ratio of -3.55 and a beta of 1.19. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.83 and a current ratio of 6.83. The stock’s 50-day moving average is $13.83 and its two-hundred day moving average is $11.82.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.01). Equities analysts expect that Eiger Biopharmaceuticals Inc will post -2.48 earnings per share for the current fiscal year.
A number of brokerages have issued reports on EIGR. Wedbush reaffirmed a “buy” rating and issued a $35.00 target price on shares of Eiger Biopharmaceuticals in a research report on Monday, January 6th. ValuEngine upgraded Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 24th. LADENBURG THALM/SH SH boosted their price target on Eiger Biopharmaceuticals from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. BidaskClub downgraded Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Finally, Gilford Securities started coverage on Eiger Biopharmaceuticals in a research note on Monday, December 16th. They set an “average” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $22.74.
A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Eiger Biopharmaceuticals by 27.0% in the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 30,018 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 6,385 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Eiger Biopharmaceuticals by 13.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 60,803 shares of the biotechnology company’s stock valued at $906,000 after acquiring an additional 7,443 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at about $43,000. Victory Capital Management Inc. increased its holdings in shares of Eiger Biopharmaceuticals by 81.5% during the 4th quarter. Victory Capital Management Inc. now owns 7,221 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 3,242 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Eiger Biopharmaceuticals by 2.7% during the 4th quarter. State Street Corp now owns 442,550 shares of the biotechnology company’s stock valued at $6,594,000 after acquiring an additional 11,458 shares during the last quarter. 84.59% of the stock is owned by hedge funds and other institutional investors.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company’s lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Eiger Biopharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
